PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29351452-4 2018 At the same time, nitric oxide, potentially a cell protective factor, has been shown to be upregulated by intracellular angiotensin II. Nitric Oxide 18-30 angiotensinogen Homo sapiens 120-134 29372262-9 2018 Hypertension also stimulates release of endothelins, vasoconstrictor prostanoids, angiotensin II, inflammatory cytokines, xanthine oxidase and, thereby, reduces bioavailability of nitric oxide. Nitric Oxide 180-192 angiotensinogen Homo sapiens 82-96 29504268-7 2018 Third, the same high dose of Ang II impaired aortic relaxation in response to the nitric oxide (NO) donor nitroprusside without impairing aortic endothelium-dependent relaxation. Nitric Oxide 82-94 angiotensinogen Homo sapiens 29-35 27092079-0 2016 Adiponectin Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Remodeling through Nitric Oxide and the RhoA/ROCK Pathway. Nitric Oxide 93-105 angiotensinogen Homo sapiens 23-37 27079272-9 2016 The requirement for ONOO(-) in transducing Ang II signaling identifies ONOO(-), which has been viewed as a reactive damaging byproduct of superoxide and nitric oxide, as a mediator of GPCR-CaMKII signaling. Nitric Oxide 153-165 angiotensinogen Homo sapiens 43-49 28849094-0 2017 Hydrogen sulfide facilities production of nitric oxide via the Akt/endothelial nitric oxide synthases signaling pathway to protect human umbilical vein endothelial cells from injury by angiotensin II. Nitric Oxide 42-54 angiotensinogen Homo sapiens 185-199 28715643-1 2017 During exposure to ischemia-reperfusion (I/R) insult, angiotensin II (AngII)-induced endothelin-1 (ET-1) upregulation in endothelial cells progressively impairs nitric oxide (NO) bioavailability while increasing levels of superoxide anion (O2-) and leading to the onset of endothelial dysfunction. Nitric Oxide 161-173 angiotensinogen Homo sapiens 54-68 28715643-1 2017 During exposure to ischemia-reperfusion (I/R) insult, angiotensin II (AngII)-induced endothelin-1 (ET-1) upregulation in endothelial cells progressively impairs nitric oxide (NO) bioavailability while increasing levels of superoxide anion (O2-) and leading to the onset of endothelial dysfunction. Nitric Oxide 161-173 angiotensinogen Homo sapiens 70-75 28344559-8 2017 Cycloxygenase-2 inhibition significantly limited the increase in 8-hydroxydeoxyguanosine, nitrotyrosine and the decrease in nitric oxide metabolites induced by angiotensin II infusion, though no changes in advanced oxidation protein products and endothelin-1 concentrations were observed. Nitric Oxide 124-136 angiotensinogen Homo sapiens 160-174 27748925-3 2016 The results of the present study demonstrated that AngII significantly upregulated the expression levels of ET-1, glucose-regulated protein 78, CCAAT-enhancer-binding protein homologous protein, phosphorylated (p)-p65 and inducible nitric oxide synthase; stimulated nitric oxide production; suppressed the expression and activity of cystathionine-gamma-lyase (CSE), a H2S synthetase; and decreased cell viability. Nitric Oxide 232-244 angiotensinogen Homo sapiens 51-56 25436932-2 2015 Specifically, it is already clear that endocrine system acts by secreting vasopressin (AVP), oxytocin (OT) and angiotensin II (ANG II), and that gaseous molecules, such as nitric oxide (NO) and carbon monoxide (CO), play an important role in modulating the neurohypophyseal secretion as well as ANG II production and thirst. Nitric Oxide 172-184 angiotensinogen Homo sapiens 295-301 26778209-3 2016 METHODS AND RESULTS: Angiotensin II (100 nM, 8 h) induced dysfunction, characterized by suppressed nitric oxide availability (85 +- 4% p<0.05) and increased superoxide production (136 +- 5 %, p<0.001). Nitric Oxide 99-111 angiotensinogen Homo sapiens 21-35 26778209-5 2016 Quercetin (3 muM, 8 h) prevented angiotensin II induced changes in nitric oxide and superoxide levels, but no effect upon nitric oxide or superoxide in control cells. Nitric Oxide 67-79 angiotensinogen Homo sapiens 33-47 26778209-8 2016 CONCLUSION: Physiologically obtainable quercetin concentrations are capable of ameliorating angiotensin II-induced endothelial nitric oxide and superoxide imbalance via protein kinase C-independent restoration of p47(phox) gene and protein expression. Nitric Oxide 127-139 angiotensinogen Homo sapiens 92-106 28105253-9 2016 The reduction in the generation of nitric oxide (NO) and expression of eNOS phosphorylation (Ser1177) in human umbilical vein endothelial cells caused by angiotensin II (Ang II) were restored by DMC or celecoxib. Nitric Oxide 35-47 angiotensinogen Homo sapiens 154-168 28105253-9 2016 The reduction in the generation of nitric oxide (NO) and expression of eNOS phosphorylation (Ser1177) in human umbilical vein endothelial cells caused by angiotensin II (Ang II) were restored by DMC or celecoxib. Nitric Oxide 35-47 angiotensinogen Homo sapiens 170-176 25700580-3 2015 Angiotensin II contributes to the production and release of oxygen reactive species that react with nitric oxide, inactivating its effects. Nitric Oxide 100-112 angiotensinogen Homo sapiens 0-14 24511122-0 2014 Angiotensin II dose-dependently stimulates human renal proximal tubule transport by the nitric oxide/guanosine 3",5"-cyclic monophosphate pathway. Nitric Oxide 88-100 angiotensinogen Homo sapiens 0-14 25312438-0 2015 Nitrate, nitrite, and nitric oxide find a home in the kidney by offsetting angiotensin II-mediated hypertension. Nitric Oxide 22-34 angiotensinogen Homo sapiens 75-89 23657857-0 2013 Nitric oxide-angiotensin II interactions and renal hemodynamic function in patients with uncomplicated type 1 diabetes. Nitric Oxide 0-12 angiotensinogen Homo sapiens 13-27 24486907-1 2014 Exposure to pro-inflammatory cytokines, such as Angiotensin II, endothelin-1 or TNF leads to endothelial dysfunction, characterized by the reduced production of nitric oxide via endothelial nitric oxide synthase (eNOS). Nitric Oxide 161-173 angiotensinogen Homo sapiens 48-62 24745027-2 2014 EECs and IMCEs can exercise substantial control over the contractility of cardiomyocytes by releasing various factors such as nitric oxide (NO) via a constitutive endothelial NO-synthase (eNOS), endothelin-1, prostaglandins, angiotensin II, peptide growth factors, and neuregulin-1. Nitric Oxide 126-138 angiotensinogen Homo sapiens 225-239 24891935-4 2014 Loss of relaxation due to inflammation and oxidative injury of the endothelium by angiotensin II leading to inhibition of endothelium-dependent nitric oxide production is the major contributors of the alcohol-induced hypertension. Nitric Oxide 144-156 angiotensinogen Homo sapiens 82-96 22028412-6 2012 An inhibitor of mTOR, rapamycin, attenuated the ANG II-stimulated phosphorylation of p70S6K and phosphorylation of IRS-1 (Ser(636/639)) and blocked the ability of ANG II to impair insulin-stimulated phosphorylation of eNOS, nitric oxide production, and mesenteric-arteriole vasodilation. Nitric Oxide 224-236 angiotensinogen Homo sapiens 48-54 22859713-0 2013 Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy. Nitric Oxide 105-117 angiotensinogen Homo sapiens 0-14 23348709-4 2013 Coenzyme Q10 (10muM) prevented the actions of angiotensin II (100nM): overproduction of reactive oxygen species, increases in expression of p22(phox) and Nox2 subunits of NADPH oxidase, and inhibition of insulin-induced nitric oxide production. Nitric Oxide 220-232 angiotensinogen Homo sapiens 46-60 23472883-7 2013 Decreased nitric oxide availability also plays a significant role in the development of advanced lesions of diabetic nephropathy through disruption of glomerular autoregulation, uncontrolled VEGF action, release of prothrombotic substances by endothelial cells and angiotensin-II-independent aldosterone production. Nitric Oxide 10-22 angiotensinogen Homo sapiens 265-279 21481898-0 2012 Angiotensin-II induced nitric oxide production during buffalo sperm capacitation and acrosome reaction. Nitric Oxide 23-35 angiotensinogen Homo sapiens 0-14 21481898-1 2012 The present study was designed to see the effects of Angiotensin-II (Ang-II) on buffalo sperm capacitation, acrosome reaction (AR), and its relation to nitric oxide (NO()) production. Nitric Oxide 152-164 angiotensinogen Homo sapiens 53-67 21481898-1 2012 The present study was designed to see the effects of Angiotensin-II (Ang-II) on buffalo sperm capacitation, acrosome reaction (AR), and its relation to nitric oxide (NO()) production. Nitric Oxide 152-164 angiotensinogen Homo sapiens 69-75 22124804-8 2012 The stimulation of renin secretion by drugs that inhibit angiotensin II formation or action results from the convergent activation of cAMP probably through indirect augmentation of the activity of PGE(2) and PGI(2) receptors, beta-adrenergic receptors, and nitric oxide. Nitric Oxide 257-269 angiotensinogen Homo sapiens 57-71 22028412-6 2012 An inhibitor of mTOR, rapamycin, attenuated the ANG II-stimulated phosphorylation of p70S6K and phosphorylation of IRS-1 (Ser(636/639)) and blocked the ability of ANG II to impair insulin-stimulated phosphorylation of eNOS, nitric oxide production, and mesenteric-arteriole vasodilation. Nitric Oxide 224-236 angiotensinogen Homo sapiens 163-169 21729921-5 2011 The effect of propofol on Ang II-modulated NADPH oxidase expression and activity, nitric oxide synthase III (NOSIII) expression and phosphorylation and activity, lipid peroxidation, superoxide anion generation, nitric oxide production, caspase activity, and protein expression of cytochrome c, Bcl-2, and C-IAP-1 were measured. Nitric Oxide 82-94 angiotensinogen Homo sapiens 26-32 21124322-7 2011 By interacting with its receptor Mas, angiotensin-(1-7) induces the release of nitric oxide from endothelial cells and thereby counteracts the effects of angiotensin II. Nitric Oxide 79-91 angiotensinogen Homo sapiens 154-168 21358315-0 2011 Angiotensin II upregulation of cardiomyocyte adiponectin production is nitric oxide/cyclic GMP dependent. Nitric Oxide 71-83 angiotensinogen Homo sapiens 0-14 21511303-0 2011 Effect of angiotensin II and its receptor antagonists on human corpus cavernous contractility and oxidative stress: modulation of nitric oxide mediated relaxation. Nitric Oxide 130-142 angiotensinogen Homo sapiens 10-24 21921604-8 2011 The effects of adrenergic and Ang II activities are counteracted by actions of nitric oxide and prostaglandins within the kidney. Nitric Oxide 79-91 angiotensinogen Homo sapiens 30-36 21210749-0 2011 Nitric oxide modulates reactivity to angiotensin II in internal mammary arterial grafts in hypertensive patients without associated risk factors. Nitric Oxide 0-12 angiotensinogen Homo sapiens 37-51 20502352-3 2010 In the hypothalamic paraventricular nucleus, Ang II has AT1 receptor-mediated sympathoexcitatory effects and enhances nitric oxide formation, which in turn inhibits the Ang II effects through a GABAergic mechanism. Nitric Oxide 118-130 angiotensinogen Homo sapiens 45-51 20582734-5 2010 Angiotensin II, acting via the type 1 receptors, induces inflammation and oxidative stress, leading to impaired insulin signaling, reduced nitric oxide availability, and vasoconstriction. Nitric Oxide 139-151 angiotensinogen Homo sapiens 0-14 20489655-5 2010 The experimental results showed that the cytotoxic effects of Ang II on human umbilical vein endothelial cells were significantly ameliorated by atorvastatin pretreatment (LDH tests, MTT assay, and propdium iodide (PI)/Annexin V-stating analysis), and atorvastatin treatment simultaneously enhanced expression of endothelial nitric oxide synthase and yielded of nitric oxide (NO) and cyclic guanosine monophosphate, but both effects were attenuated by the B2Rs antagonist HOE-140. Nitric Oxide 325-337 angiotensinogen Homo sapiens 62-68 18765096-5 2008 Angiotensin II in brain neurons affects other neurons both through activation of angiotensin receptors and via generation of nitric oxide and reactive oxygen molecules. Nitric Oxide 125-137 angiotensinogen Homo sapiens 0-14 18855718-6 2008 Angiotensin II acting through the AT1 receptor can inhibit insulin-induced nitric oxide (NO) production by activating ERK 1/2 and JNK and enhances the activity of NADPH oxidase that leads to an increased reactive oxygen species generation. Nitric Oxide 75-87 angiotensinogen Homo sapiens 0-14 18619489-7 2008 The intracellular effects of Ang II are influenced by nitric oxide (NO)/cGMP-dependent cross talk and are mediated by the release of autocrine factors, such as transforming growth factor (TGF)-beta1 and interleukin (IL)-6. Nitric Oxide 54-66 angiotensinogen Homo sapiens 29-35 18945823-0 2009 Angiotensin II-induced contraction is attenuated by nitric oxide in afferent arterioles from the nonclipped kidney in 2K1C. Nitric Oxide 52-64 angiotensinogen Homo sapiens 0-14 18182246-0 2008 Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Nitric Oxide 80-92 angiotensinogen Homo sapiens 0-14 18501011-1 2008 We study the voltage dependent calcium channels and nitric oxide involvement in angiotensin II-induced pressor effect. Nitric Oxide 52-64 angiotensinogen Homo sapiens 80-94 18501011-8 2008 These data showed the involvement of L-Type calcium channel and a free radical gas nitric oxide in the central control of angiotensin II-induced pressor effect. Nitric Oxide 83-95 angiotensinogen Homo sapiens 122-136 18182232-0 2008 Modulation by bradykinin and nitric oxide of angiotensin II-induced apoptosis in a vascular smooth muscle cell phenotype. Nitric Oxide 29-41 angiotensinogen Homo sapiens 45-59 18182246-3 2008 Using an animal model of hypertension, we have demonstrated that Ang II produces a vasodilator effect through the AT2 receptor via the bradykinin (BK)-dependent activation of endothelial nitric oxide (NO) synthase. Nitric Oxide 187-199 angiotensinogen Homo sapiens 65-71 18182232-3 2008 We asked whether bradykinin (BK) and nitric oxide (NO) could modulate Ang II-induced SMC apoptosis. Nitric Oxide 37-49 angiotensinogen Homo sapiens 70-76 18090670-6 2008 SUMMARY: Disparities between the activities of angiotensin II and nitric oxide are pervasive in a variety of acute and chronic kidney diseases. Nitric Oxide 66-78 angiotensinogen Homo sapiens 47-61 17526929-7 2007 Ang II pre-treatment reduced FLS apoptotic response to serum starvation and nitric oxide (NO) exposure. Nitric Oxide 76-88 angiotensinogen Homo sapiens 0-6 20409863-4 2007 This profile is proinflammatory, and is manifested by intimal infiltration of fetal cells, increased production of angiotensin II (Ang II)-signaling pathway molecules, eg, matrix metalloproteases (MMPs), and monocyte chemoattractant protein (MCP-1), transforming growth factor B1 (TGF-beta1), enhanced activation of MMPs, TGF-beta, and NADPH oxidase, and reduced nitric oxide (NO) bioavailability. Nitric Oxide 363-375 angiotensinogen Homo sapiens 131-137 17717927-0 2007 [Effect of tanshinone II A on angiotensin II induced nitric oxide production and endothelial nitric oxide synthase gene expression in cultured porcine aortic endothelial cells]. Nitric Oxide 53-65 angiotensinogen Homo sapiens 30-44 17222945-1 2007 Growing evidence suggests that endocardial endothelial cells (EECs) may play an important role in the regulation of cardiac function by releasing several cardioactive factors such as endothelin-1 (ET-1), Angiotensin II (Ang II) and nitric oxide (NO). Nitric Oxide 232-244 angiotensinogen Homo sapiens 220-226 17346243-6 2007 Less is known about the endothelial AngII signalling; however, recent studies suggest the endothelial AngII signalling positively, as well as negatively, regulates the NO (nitric oxide) signalling pathway and, thereby, modulates endothelial dysfunction. Nitric Oxide 172-184 angiotensinogen Homo sapiens 102-107 17444277-5 2007 Such temporal adaptation occurs via modulators such as nitric oxide (NO), primarily derived from NOS-1, angiotensin II and COX-2 products. Nitric Oxide 55-67 angiotensinogen Homo sapiens 104-118 17254516-3 2007 To the same degree, angiotensin II impairs insulin signaling, induces inflammation via the nuclear factor-kappaB pathway, and reduces nitric oxide availability and facilitates vasoconstriction, leading to insulin resistance and endothelial dysfunction. Nitric Oxide 134-146 angiotensinogen Homo sapiens 20-34 17143071-0 2007 Angiotensin II-nitric oxide interaction in the kidney. Nitric Oxide 15-27 angiotensinogen Homo sapiens 0-14 17143071-2 2007 Angiotensin II induces nitric oxide release, but the role of angiotensin II receptors here is not fully understood. Nitric Oxide 23-35 angiotensinogen Homo sapiens 0-14 17143071-3 2007 Further, the angiotensin II-nitric oxide interaction can be modulated by reactive oxygen species. Nitric Oxide 28-40 angiotensinogen Homo sapiens 13-27 17143071-4 2007 This review focuses on the angiotensin II-nitric oxide interaction and their modulation by reactive oxygen species in the control of renal blood flow. Nitric Oxide 42-54 angiotensinogen Homo sapiens 27-41 17143071-5 2007 RECENT FINDINGS: Ideas about the role of angiotensin II type 1 and angiotensin II type 2 receptors are extended by the observation of angiotensin II type 1-mediated nitric oxide release with direct effects on vascular tone, tubuloglomerular feedback and sympathetic neurotransmission. Nitric Oxide 165-177 angiotensinogen Homo sapiens 41-55 17143071-5 2007 RECENT FINDINGS: Ideas about the role of angiotensin II type 1 and angiotensin II type 2 receptors are extended by the observation of angiotensin II type 1-mediated nitric oxide release with direct effects on vascular tone, tubuloglomerular feedback and sympathetic neurotransmission. Nitric Oxide 165-177 angiotensinogen Homo sapiens 67-81 17143071-5 2007 RECENT FINDINGS: Ideas about the role of angiotensin II type 1 and angiotensin II type 2 receptors are extended by the observation of angiotensin II type 1-mediated nitric oxide release with direct effects on vascular tone, tubuloglomerular feedback and sympathetic neurotransmission. Nitric Oxide 165-177 angiotensinogen Homo sapiens 67-81 17143071-7 2007 Angiotensin II-nitric oxide interactions are modulated by reactive oxygen species, as shown by angiotensin II type 1-mediated activation of superoxide and depression of antioxidant enzymes leading to reduced nitric oxide concentration - mechanisms that may be also important in angiotensin II-dependent hypertension. Nitric Oxide 15-27 angiotensinogen Homo sapiens 0-14 17143071-7 2007 Angiotensin II-nitric oxide interactions are modulated by reactive oxygen species, as shown by angiotensin II type 1-mediated activation of superoxide and depression of antioxidant enzymes leading to reduced nitric oxide concentration - mechanisms that may be also important in angiotensin II-dependent hypertension. Nitric Oxide 15-27 angiotensinogen Homo sapiens 95-109 17143071-7 2007 Angiotensin II-nitric oxide interactions are modulated by reactive oxygen species, as shown by angiotensin II type 1-mediated activation of superoxide and depression of antioxidant enzymes leading to reduced nitric oxide concentration - mechanisms that may be also important in angiotensin II-dependent hypertension. Nitric Oxide 15-27 angiotensinogen Homo sapiens 278-292 17143071-7 2007 Angiotensin II-nitric oxide interactions are modulated by reactive oxygen species, as shown by angiotensin II type 1-mediated activation of superoxide and depression of antioxidant enzymes leading to reduced nitric oxide concentration - mechanisms that may be also important in angiotensin II-dependent hypertension. Nitric Oxide 208-220 angiotensinogen Homo sapiens 0-14 17143071-7 2007 Angiotensin II-nitric oxide interactions are modulated by reactive oxygen species, as shown by angiotensin II type 1-mediated activation of superoxide and depression of antioxidant enzymes leading to reduced nitric oxide concentration - mechanisms that may be also important in angiotensin II-dependent hypertension. Nitric Oxide 208-220 angiotensinogen Homo sapiens 95-109 17143071-8 2007 SUMMARY: Recent studies show that angiotensin II stimulates the nitric oxide system via angiotensin II type 1 and angiotensin II type 2 receptors, whereas receptors exert different effects on renal and medullary flow. Nitric Oxide 64-76 angiotensinogen Homo sapiens 34-48 17143071-8 2007 SUMMARY: Recent studies show that angiotensin II stimulates the nitric oxide system via angiotensin II type 1 and angiotensin II type 2 receptors, whereas receptors exert different effects on renal and medullary flow. Nitric Oxide 64-76 angiotensinogen Homo sapiens 88-102 17143071-8 2007 SUMMARY: Recent studies show that angiotensin II stimulates the nitric oxide system via angiotensin II type 1 and angiotensin II type 2 receptors, whereas receptors exert different effects on renal and medullary flow. Nitric Oxide 64-76 angiotensinogen Homo sapiens 88-102 17824812-3 2007 Except vasorelaxing and antiproliferative properties per se, nitric oxide participates in antagonizing vasoconstrictive and growth promoting effects of angiotensin II, endothelins and reactive oxygen species. Nitric Oxide 61-73 angiotensinogen Homo sapiens 152-166 17213573-6 2006 Angiotensin II impairs insulin signaling, induces inflammation via the NF-kappaB pathway, reduces nitric oxide availability and facilitates vasoconstriction, leading to insulin resistance and endothelial dysfunction. Nitric Oxide 98-110 angiotensinogen Homo sapiens 0-14 16580888-0 2006 Detection of angiotensin II mediated nitric oxide release within the nucleus of the solitary tract using electron-paramagnetic resonance (EPR) spectroscopy. Nitric Oxide 37-49 angiotensinogen Homo sapiens 13-27 16515797-0 2006 Angiotensin II effect on hydraulic permeability: interaction with endothelin-1, nitric oxide, and platelet activating factor. Nitric Oxide 80-92 angiotensinogen Homo sapiens 0-14 16370314-4 2005 RESULTS: The angiotensin II-induced beta3 integrin mRNA expression was inhibited by alpha-zearalenol and 17beta-estradiol (10 nmol/L -1 micromol/L), but not influenced by ICI 182, 780, a pure competitive antagonist for estrogen receptor or a nitric oxide inhibitor Nomega-Nitro-L-arginine methyl ester hydrochloride. Nitric Oxide 242-254 angiotensinogen Homo sapiens 13-27 16223512-6 2006 Stimulation of angiotensin II increased nitric oxide (NO) production in cultured basilar arterial endothelial cells. Nitric Oxide 40-52 angiotensinogen Homo sapiens 15-29 16472178-5 2006 Less is known about endothelial cell (EC) AngII signaling than VSMCs, however, recent studies suggest that endothelial AngII signaling negatively regulates the nitric oxide (NO) signaling pathway and thereby induces endothelial dysfunction. Nitric Oxide 160-172 angiotensinogen Homo sapiens 119-124 16409566-2 2006 Experimental evidence suggests vascular responses to endogenous angiotensin II involve the nitric oxide and prostaglandin pathways. Nitric Oxide 91-103 angiotensinogen Homo sapiens 64-78 16124358-1 2005 Angiotensin-II regulates vascular tone, stimulates the release of pro-inflammatory cytokines, activates NF-kappaB, increases oxidant stress, and suppresses nitric oxide synthesis, and thus, it functions as an inflammatory molecule. Nitric Oxide 156-168 angiotensinogen Homo sapiens 0-14 20527397-3 2005 Tissue ACE-I, through their high affinity to endothelium, considerably stronger prevents the local synthesis of angiotensin II (Ang II) and by inhibition of kininase II causes the subsequent increase of bradykinin level and mediated by BK2 receptor release of nitric oxide (NO), prostacycline (PGI2) and tissue type plasminogen activator (t-PA). Nitric Oxide 260-272 angiotensinogen Homo sapiens 112-126 15728793-0 2005 Angiotensin II elevates nitric oxide synthase 3 expression and nitric oxide production via a mitogen-activated protein kinase cascade in ovine fetoplacental artery endothelial cells. Nitric Oxide 24-36 angiotensinogen Homo sapiens 0-14 15728793-2 2005 These high levels of ANG II may promote production vasodilators such as nitric oxide (NO). Nitric Oxide 72-84 angiotensinogen Homo sapiens 21-27 15790666-0 2005 Angiotensin II regulation of ovine fetoplacental artery endothelial functions: interactions with nitric oxide. Nitric Oxide 97-109 angiotensinogen Homo sapiens 0-14 15790666-5 2005 Recent data from our laboratories suggest that Ang II stimulates cell proliferation and increases endothelial nitric oxide synthase (eNOS) and production of nitric oxide (NO) in ovine fetoplacental artery endothelial cells. Nitric Oxide 110-122 angiotensinogen Homo sapiens 47-53 15694707-3 2005 Recent evidence suggests that a healthy coronary microvascular endothelium opposes this effect by serving as a paracrine source of nitric oxide (NO), a natural antagonist of AngII activity, and that up-regulation of this mechanism can account for the protective role of bradykinin with respect to LVH. Nitric Oxide 131-143 angiotensinogen Homo sapiens 174-179 15763077-1 2005 Nitric oxide (NO) has been shown to play a key role in the regulation of cardiac hypertrophy and fibrosis in response to myocardial ischemia in part by antagonizing the action of angiotensin II (Ang II). Nitric Oxide 0-12 angiotensinogen Homo sapiens 179-193 15763077-1 2005 Nitric oxide (NO) has been shown to play a key role in the regulation of cardiac hypertrophy and fibrosis in response to myocardial ischemia in part by antagonizing the action of angiotensin II (Ang II). Nitric Oxide 0-12 angiotensinogen Homo sapiens 195-201 15638745-6 2005 However, costimulation of the angiotensin II type 2 (AT2) receptor appears to increase nitric oxide and thus causes some bradykinin-like effects. Nitric Oxide 87-99 angiotensinogen Homo sapiens 30-44 15834276-0 2005 Angiotensin II as the link between nitric oxide and neuroadrenergic function. Nitric Oxide 35-47 angiotensinogen Homo sapiens 0-14 15874906-1 2005 Angiotensin-II, a product of angiotensin converting enzyme (ACE) action, regulates vascular tone, stimulates the release of pro-inflammatory cytokines, activates NFkappaB, increases oxidant stress, and suppresses nitric oxide synthesis. Nitric Oxide 213-225 angiotensinogen Homo sapiens 0-14 15691500-6 2005 DETA NONOate, a nitric oxide donor, inhibited the basal, angiotensin-II-stimulated, and 25-hydroxycholesterol-stimulated syntheses of these steroids in ZG cells in a concentration-dependent manner. Nitric Oxide 16-28 angiotensinogen Homo sapiens 57-71 15780486-6 2005 Angiotensin II stimulates nicotinamide adenine dinucleotide phosphate/nicotinamide adenine dinucleotide oxidase in endothelium, smooth muscle cells, and the adventitia of blood vessel to generate reactive oxygen species, leading to endothelial dysfunction, growth, and inflammation, upregulation of endothelin-1, adhesion molecules, nuclear factor-kappa B, and other inflammatory mediators, as well as increased breakdown of nitric oxide and uncoupling of nitric oxide synthase, contribute to the progression of vascular disease and atherogenesis. Nitric Oxide 425-437 angiotensinogen Homo sapiens 0-14 15283761-5 2004 Counter-regulatory vasodilator mechanisms (e.g. nitric oxide), at least partly mediated through cross-talk between the vasculature and the tubular epithelium, protect the medullary circulation from the vasoconstrictor effects of hormonal factors such as angiotensin II. Nitric Oxide 48-60 angiotensinogen Homo sapiens 254-268 15610248-3 2005 As nitric oxide production via iNOS can inhibit CYP AA metabolism, we tested the hypothesis that by blocking iNOS or by supplementing eicosapentanoic acid (EPA), which can serve as an alternative CYP substrate, Ang II-induced vasculopathy could be ameliorated. Nitric Oxide 3-15 angiotensinogen Homo sapiens 211-217 20021068-5 2005 Statins reduce the generation of reactive oxygen species by vascular NAD(P)H oxidase, inhibit the respiratory burst of phagocytes, antagonize the prooxidant effect of angiotensin II and endothelin-1, and increase the synthesis of vascular nitric oxide. Nitric Oxide 239-251 angiotensinogen Homo sapiens 167-181 15155270-0 2004 Angiotensin II stimulates nitric oxide production in pulmonary artery endothelium via the type 2 receptor. Nitric Oxide 26-38 angiotensinogen Homo sapiens 0-14 15155270-1 2004 We previously reported that angiotensin II stimulates an increase in nitric oxide production in pulmonary artery endothelial cells. Nitric Oxide 69-81 angiotensinogen Homo sapiens 28-42 15155270-2 2004 The aims of this study were to determine which receptor subtype mediates the angiotensin II-dependent increase in nitric oxide production and to investigate the roles of the angiotensin type 1 and type 2 receptors in modulating angiotensin II-dependent vasoconstriction in pulmonary arteries. Nitric Oxide 114-126 angiotensinogen Homo sapiens 77-91 15155270-4 2004 Treatment of the endothelial cells with PD-123319, a type 2 receptor antagonist, prevented the angiotensin II-dependent increase in nitric oxide synthase mRNA, protein levels, and nitric oxide production. Nitric Oxide 132-144 angiotensinogen Homo sapiens 95-109 15155270-6 2004 Pretreatment of the endothelial cells with either PD-123319 or an anti-angiotensin II antibody prevented this losartan enhancement of nitric oxide production. Nitric Oxide 134-146 angiotensinogen Homo sapiens 71-85 15155270-8 2004 These data demonstrate that angiotensin II stimulates an increase in nitric oxide synthase mRNA, protein expression, and nitric oxide production via the type 2 receptor, whereas signaling via the type 1 receptor negatively regulates nitric oxide production in the pulmonary endothelium. Nitric Oxide 69-81 angiotensinogen Homo sapiens 28-42 15155270-8 2004 These data demonstrate that angiotensin II stimulates an increase in nitric oxide synthase mRNA, protein expression, and nitric oxide production via the type 2 receptor, whereas signaling via the type 1 receptor negatively regulates nitric oxide production in the pulmonary endothelium. Nitric Oxide 121-133 angiotensinogen Homo sapiens 28-42 15155270-9 2004 This endothelial, type 2 receptor-dependent increase in nitric oxide may serve to counterbalance the angiotensin II-dependent vasoconstriction in smooth muscle cells, ultimately regulating pulmonary vascular tone. Nitric Oxide 56-68 angiotensinogen Homo sapiens 101-115 15158138-5 2004 Secondly, ANG stimulates the release of nitric oxide (NO)/cGMP via AT(2) receptor activation, as described in the aorta, heart, and kidney. Nitric Oxide 40-52 angiotensinogen Homo sapiens 10-13 14978155-14 2004 Angiotensin II (AngII) activates NADPH oxidases, leading to production of the superoxide anion and decreased availability of nitric oxide (NO), further impairing vascular function. Nitric Oxide 125-137 angiotensinogen Homo sapiens 0-14 15295720-0 2004 Tonic levels of angiotensin II reduce tonic levels of vascular nitric oxide even in salt-replete man. Nitric Oxide 63-75 angiotensinogen Homo sapiens 16-30 15044323-0 2004 Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Nitric Oxide 77-89 angiotensinogen Homo sapiens 0-14 14978155-14 2004 Angiotensin II (AngII) activates NADPH oxidases, leading to production of the superoxide anion and decreased availability of nitric oxide (NO), further impairing vascular function. Nitric Oxide 125-137 angiotensinogen Homo sapiens 16-21 15142663-3 2004 Recent evidence suggests that a healthy coronary microvascular endothelium opposes this effect by serving as a paracrine source of nitric oxide (NO), a natural antagonist of AngII activity, and that up-regulation of this mechanism can account for the protective role of bradykinin with respect to LVH. Nitric Oxide 131-143 angiotensinogen Homo sapiens 174-179 14704595-4 2004 The oxidative stress produced by Ang II leads to enhanced low-density lipoprotein oxidation and degradation of nitric oxide, an important vascular protective molecule capable of retarding atherosclerosis progression. Nitric Oxide 111-123 angiotensinogen Homo sapiens 33-39 12919932-5 2003 First, the inducible nitric oxide inhibitor aminoguanidine prevents angiotensin II-induced DNA damage and apoptosis. Nitric Oxide 21-33 angiotensinogen Homo sapiens 68-82 12919932-6 2003 Second, based on ligation-mediated PCR, the pattern of angiotensin II-induced DNA damage resembles peroxynitritemediated damage rather than damage caused by either superoxide or nitric oxide. Nitric Oxide 178-190 angiotensinogen Homo sapiens 55-69 14510783-0 2003 Facilitation of renal autoregulation by angiotensin II is mediated through modulation of nitric oxide. Nitric Oxide 89-101 angiotensinogen Homo sapiens 40-54 14510783-12 2003 We suggest that Ang II facilitates autoregulation by a tubuloglomerular feedback-dependent mechanism through AT1 receptor-mediated depletion of nitric oxide, probably by stimulating generation of superoxide. Nitric Oxide 144-156 angiotensinogen Homo sapiens 16-22 14586712-4 2003 Using these preparations, we have found that angiotensin II (Ang II) causes much stronger constriction in Ef- than in Af-Arts and that this difference is mediated by nitric oxide (NO)- and prostaglandin (PG)-induced modulation of Ang II action in the Af-Art. Nitric Oxide 166-178 angiotensinogen Homo sapiens 45-59 12763754-0 2003 Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB. Nitric Oxide 25-37 angiotensinogen Homo sapiens 0-14 15018246-3 2003 Studies in animal models treated with the nitric oxide inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME), angiotensin II and salt, with and without adrenalectomy, have demonstrated that myocardial damage can be eliminated by adrenalectomy or by administering an aldosterone receptor antagonist and is induced by adding back aldosterone to adrenalectomized animals. Nitric Oxide 42-54 angiotensinogen Homo sapiens 114-128 14586712-4 2003 Using these preparations, we have found that angiotensin II (Ang II) causes much stronger constriction in Ef- than in Af-Arts and that this difference is mediated by nitric oxide (NO)- and prostaglandin (PG)-induced modulation of Ang II action in the Af-Art. Nitric Oxide 166-178 angiotensinogen Homo sapiens 61-67 12862295-5 2003 The antiatherogenic properties of ACE inhibitors and ARBs may derive from inhibition or blockade of angiotensin II, now recognized as an agent that increases oxidative stress.Angiotensin-converting enzyme inhibition and angiotensin-receptor blockade also increase endothelial nitric oxide formation, which improves endothelial function. Nitric Oxide 276-288 angiotensinogen Homo sapiens 100-114 12763763-0 2003 Angiotensin II inhibits endothelial cell motility through an AT1-dependent oxidant-sensitive decrement of nitric oxide availability. Nitric Oxide 106-118 angiotensinogen Homo sapiens 0-14 12589179-7 2003 The angiotensin II receptors involved in the inflammatory process and the interaction between angiotensin II and nitric oxide in mediating vascular inflammation have been identified. Nitric Oxide 113-125 angiotensinogen Homo sapiens 4-18 14646364-10 2003 Angiotensin II binding, AT1 mRNA expression and calcium response to angiotensin II were decreased in presence of the nitric oxide donor (p < 0.01). Nitric Oxide 117-129 angiotensinogen Homo sapiens 0-14 12595345-3 2003 In this study, we directly assessed the vasomotor action of Ang II in isolated porcine coronary arterioles and also examined whether Ang II can modulate endothelium-dependent nitric oxide (NO)-mediated dilation via superoxide production. Nitric Oxide 175-187 angiotensinogen Homo sapiens 133-139 12480559-0 2003 Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. Nitric Oxide 0-12 angiotensinogen Homo sapiens 62-76 12480559-2 2003 This study aims to assess the role of endogenous nitric oxide (NO) in the reduced vascular responsiveness to angiotensin II (ANG-II) in eight patients with preascitic cirrhosis compared with eight age- and sex-matched healthy controls. Nitric Oxide 49-61 angiotensinogen Homo sapiens 109-123 12480559-2 2003 This study aims to assess the role of endogenous nitric oxide (NO) in the reduced vascular responsiveness to angiotensin II (ANG-II) in eight patients with preascitic cirrhosis compared with eight age- and sex-matched healthy controls. Nitric Oxide 49-61 angiotensinogen Homo sapiens 125-131 12511527-3 2003 Furthermore, we tested the hypothesis that the effect of interstitial angiotensin II is modulated by nitric oxide. Nitric Oxide 101-113 angiotensinogen Homo sapiens 70-84 14646364-10 2003 Angiotensin II binding, AT1 mRNA expression and calcium response to angiotensin II were decreased in presence of the nitric oxide donor (p < 0.01). Nitric Oxide 117-129 angiotensinogen Homo sapiens 68-82 12243360-4 2002 Although its pathophysiology is not well defined, a reduced cardiovascular response to vasopressor agents (such as norepinephrine and angiotensin II), associated with a down-regulation of their receptors, as well as an increased production of vasodilators (such as nitric oxide or adrenomedullin) are possibly involved. Nitric Oxide 265-277 angiotensinogen Homo sapiens 134-148 12242266-0 2002 Tubulovascular nitric oxide crosstalk: buffering of angiotensin II-induced medullary vasoconstriction. Nitric Oxide 15-27 angiotensinogen Homo sapiens 52-66 11856911-5 2002 Increased oxidative stress, common to different diseases including diabetes mellitus and hypertension, is also a determinant player in the interaction between angiotensin II and nitric oxide. Nitric Oxide 178-190 angiotensinogen Homo sapiens 159-173 12087347-0 2002 Angiotensin II attenuates the vasodilating effect of a nitric oxide donor, glyceryl trinitrate: roles of superoxide and angiotensin II type 1 receptors. Nitric Oxide 55-67 angiotensinogen Homo sapiens 0-14 12065072-6 2002 Similarly, the nitric oxide donor (Z)-1-[2-Aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (Deta-NO) blocks the angiotensin II-induced PKB activation. Nitric Oxide 15-27 angiotensinogen Homo sapiens 125-139 11753088-4 2002 Nitric oxide synthase inhibition facilitates angiotensin II related effects, which can be inhibited both by angiotensin II type 1 receptor blockers and by endothelin system inhibitors. Nitric Oxide 0-12 angiotensinogen Homo sapiens 45-59 11882637-0 2002 Renal hemodynamic control by endothelin and nitric oxide under angiotensin II blockade in man. Nitric Oxide 44-56 angiotensinogen Homo sapiens 63-77 11882637-7 2002 Because such a vasodilation is prevented by nonvasoconstricting microdoses of N(G)-nitro-L-arginine methylester, nitric oxide--endothelin balance controls substantially renal hemodynamics under angiotensin II blockade. Nitric Oxide 113-125 angiotensinogen Homo sapiens 194-208 11882637-8 2002 These findings are consistent with a rationale of the association of endothelin-A blockers with angiotensin II blockers or angiotensin-converting enzyme inhibitors in treating nitric oxide--deficient conditions such as arterial hypertension, heart failure, and chronic renal diseases. Nitric Oxide 176-188 angiotensinogen Homo sapiens 96-110 12090908-1 2002 Angiotensin-converting enzyme (ACE) activation and the de novo production of angiotensin II contribute to cardiovascular disease through direct pathological tissue effects, including vascular remodeling and inflammation, as well as indirect action on nitric oxide bioavailability and its consequences. Nitric Oxide 251-263 angiotensinogen Homo sapiens 77-91 11851644-2 2002 Our aim was to assess the hypothesis that local nitric oxide (NO) generation is also, in part, responsible for tachyphylaxis to ANGII in veins, using the Aellig dorsal hand vein technique. Nitric Oxide 48-60 angiotensinogen Homo sapiens 128-133 11941405-0 2000 Nitric oxide inhibits the expression of proto-oncogene c-fos induced by angiotensin II and endothelin-1 in cardiomyocytes. Nitric Oxide 0-12 angiotensinogen Homo sapiens 72-86 11678735-5 2001 Interestingly, nitric oxide donors microinjected into the NTS mimicked the effect of ANGII. Nitric Oxide 15-27 angiotensinogen Homo sapiens 85-90 11678735-11 2001 We conclude that ANGII activates endothelial nitric oxide synthase to release nitric oxide which enhances gamma-amino butyric acid transmission destined for circuitry mediating the baroreflex. Nitric Oxide 45-57 angiotensinogen Homo sapiens 17-22 11715356-8 2001 Calcium antagonists counteract the effects of angiotensin II and endothelin-1 at the level of vascular smooth muscle by reducing Ca2+ inflow and facilitating the vasodilator effects of nitric oxide. Nitric Oxide 185-197 angiotensinogen Homo sapiens 46-60 11811381-2 2001 When given acutely, L-arginine derivatives have an antinatriuretic effect that is overridden by elevation of perfusion pressure and both endothelin and angiotensin II play an important role in the systemic and renal haemodynamic alterations associated with impaired nitric oxide availability. Nitric Oxide 266-278 angiotensinogen Homo sapiens 137-166 11399665-0 2001 Cyclic AMP elevating agents and nitric oxide modulate angiotensin II-induced leukocyte-endothelial cell interactions in vivo. Nitric Oxide 32-44 angiotensinogen Homo sapiens 54-68 11309530-3 2001 Clinical and experimental evidence supports a pathophysiologic role for pro-inflammatory cytokines and nitric oxide (NO) in the effects of angiotensin II and norepinephrine in CHF. Nitric Oxide 103-115 angiotensinogen Homo sapiens 139-153 10766859-0 2000 Distinct effects of N-acetylcysteine and nitric oxide on angiotensin II-induced epidermal growth factor receptor phosphorylation and intracellular Ca(2+) levels. Nitric Oxide 41-53 angiotensinogen Homo sapiens 57-71 11256235-2 2000 An active component of this system, angiotensin II (Ang II), differentially regulates the production of oxyradicals, nitric oxide, prostaglandins, platelet-activating factors and bradykinins by acting through AT1 or AT2 receptor subtypes. Nitric Oxide 117-129 angiotensinogen Homo sapiens 36-50 11256235-2 2000 An active component of this system, angiotensin II (Ang II), differentially regulates the production of oxyradicals, nitric oxide, prostaglandins, platelet-activating factors and bradykinins by acting through AT1 or AT2 receptor subtypes. Nitric Oxide 117-129 angiotensinogen Homo sapiens 52-58 11022893-8 2000 However, there are a number of pathophysiologic conditions where Ang II interacts with various local autocrine and paracrine factors (such as nitric oxide [NO], eicosanoids, adenosine, and superoxide) to influence glomerular filtration rate. Nitric Oxide 142-154 angiotensinogen Homo sapiens 65-71 10862636-0 2000 Effects of angiotensin II blockade on nitric oxide blood levels in IgA nephropathy. Nitric Oxide 38-50 angiotensinogen Homo sapiens 11-25 11103753-0 2000 Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers. Nitric Oxide 94-106 angiotensinogen Homo sapiens 10-24 11103753-1 2000 BACKGROUND: Angiotensin II has been shown to induce the synthesis of endothelium-derived relaxing factor nitric oxide (NO) and endothelin in vitro. Nitric Oxide 105-117 angiotensinogen Homo sapiens 12-26 19667535-4 2000 Oxidized lipoproteins inhibit the release of the vasodilative substance nitric oxide, and angiotensin II degrades bradykinin, a potent stimulator of nitric oxide production in endothelial cells that is known to protect against atherosclerosis. Nitric Oxide 149-161 angiotensinogen Homo sapiens 90-104 10766859-4 2000 The transactivation of the epidermal growth factor receptor by angiotensin II, a process required for the activation of ERK, was inhibited by N-acetylcysteine but not by nitric oxide. Nitric Oxide 170-182 angiotensinogen Homo sapiens 63-77 10766859-6 2000 Nitric oxide, but not N-acetylcysteine, inhibited the angiotensin II-induced increase in intracellular Ca(2+). Nitric Oxide 0-12 angiotensinogen Homo sapiens 54-68 10739535-0 2000 Nitric oxide modulates angiotensin II-induced drinking behavior in the near-term ovine fetus. Nitric Oxide 0-12 angiotensinogen Homo sapiens 23-37 10739535-3 2000 This study was performed to determine whether central nitric oxide contributes to the regulation of angiotensin II-induced fetal swallowing. Nitric Oxide 54-66 angiotensinogen Homo sapiens 100-114 10739535-9 2000 CONCLUSIONS: These results demonstrate that inhibition of central nitric oxide suppresses fetal swallowing behavior in response to central angiotensin II. Nitric Oxide 66-78 angiotensinogen Homo sapiens 139-153 10698187-1 2000 During pregnancy, the uterine vasculature shows a marked increase in vasodilator production [prostacyclin (PGI2) and nitric oxide (NO)] in response to a number of agonists including angiotensin II (AII) and ATP. Nitric Oxide 117-129 angiotensinogen Homo sapiens 182-196 10739535-10 2000 We speculate that tonic nitric oxide facilitates angiotensin II swallowing stimulation by maintenance of glutamate activation of hypothalamic N -methyl-D -aspartate receptors. Nitric Oxide 24-36 angiotensinogen Homo sapiens 49-63 10928298-0 2000 Nitric oxide--angiotensin II axis in renal and cardiovascular injury. Nitric Oxide 0-12 angiotensinogen Homo sapiens 14-28 10928298-2 2000 The existence of a Nitric Oxide/Angiotensin II axis, brought modification to our ways of thinking with new and more pathophysiological approaches to the treatment of hypertension and end-organ disease. Nitric Oxide 19-31 angiotensinogen Homo sapiens 32-46 10657983-2 2000 Vascular cell experiments suggest that ANG II is a potent stimulator of free radicals such as superoxide anion, an agent known to inactivate nitric oxide and promote the formation of peroxynitrite. Nitric Oxide 141-153 angiotensinogen Homo sapiens 39-45 10579747-7 1999 However, costimulation of the angiotensin II type 2 (AT2) receptor appears to increase nitric oxide and thus to cause some bradykinin-like effects. Nitric Oxide 87-99 angiotensinogen Homo sapiens 30-44 10691781-2 2000 We now describe a novel physiological action of ANG II to release nitric oxide (NO) mediated by the AT2 receptor in both the kidney and gastrointestinal tract. Nitric Oxide 66-78 angiotensinogen Homo sapiens 48-54 10556973-4 1999 Thus, nitric oxide inhibits endothelial cell apoptosis induced by proinflammatory cytokines and proatherosclerotic factors including reactive oxygen species and angiotensin II. Nitric Oxide 6-18 angiotensinogen Homo sapiens 161-175 10523389-8 1999 In this way, a reduction in the concentration of nitric oxide (which is quenched by superoxide) along with the formation of F(2)-isoprostanes and endothelin could potentiate the vasoconstrictor effects of angiotensin II. Nitric Oxide 49-61 angiotensinogen Homo sapiens 205-219 10981059-10 1999 In the absence of the AT(2) receptor, sustained angiotensin II pressor and antinatriuretic hypersensitivity occurs, mediated by a deficiency of bradykinin, nitric oxide, and cyclic GMP. Nitric Oxide 156-168 angiotensinogen Homo sapiens 48-62 10446131-1 1999 Induction by ATII antagonized by nitric oxide. Nitric Oxide 33-45 angiotensinogen Homo sapiens 13-17 10334805-2 1999 The mechanism through which it exerts this effect is unknown but may be due to increased angiotensin II-induced nitric oxide (NO) breakdown and/or reduced bradykinin-mediated NO release. Nitric Oxide 112-124 angiotensinogen Homo sapiens 89-103 10361443-1 1999 Recent advances in the molecular characterization for angiotensin II (A II) related to nitric oxide, endothelin-1, prostaglandin, and adrenomedullin are reviewed. Nitric Oxide 87-99 angiotensinogen Homo sapiens 54-68 10361443-1 1999 Recent advances in the molecular characterization for angiotensin II (A II) related to nitric oxide, endothelin-1, prostaglandin, and adrenomedullin are reviewed. Nitric Oxide 87-99 angiotensinogen Homo sapiens 70-74 10073598-0 1999 Angiotensin II-stimulated nitric oxide release from porcine pulmonary endothelium is mediated by angiotensin IV. Nitric Oxide 26-38 angiotensinogen Homo sapiens 0-14 10073598-1 1999 In this study, a nitric oxide (NO) sensor was used to examine the ability of angiotensin II (AngII), AngIV, and bradykinin (Bk) to stimulate NO release from porcine pulmonary artery (PPAE) and porcine aortic endothelial (PAE) cells and to explore the mechanism of the AngII-stimulated NO release. Nitric Oxide 17-29 angiotensinogen Homo sapiens 77-91 10614144-7 1999 As a consequence of these mechanisms, basal and/or stimulated nitric oxide availability is reduced, allowing vasoconstrictor systems, such as angiotensin II, sympathetic nervous system and others to over-express their actions. Nitric Oxide 62-74 angiotensinogen Homo sapiens 142-156 10069678-0 1999 Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo. Nitric Oxide 34-46 angiotensinogen Homo sapiens 70-84 10069678-2 1999 It was recently suggested that the endothelium may influence the actions of angiotensin II by production of, for example, nitric oxide and superoxide. Nitric Oxide 122-134 angiotensinogen Homo sapiens 76-90 10193813-1 1999 BACKGROUND: The role of angiotensin II (Ang II) in the systemic and renal responses to acute nitric oxide (NO) synthesis inhibition has not been studied in detail in healthy humans. Nitric Oxide 93-105 angiotensinogen Homo sapiens 24-38 10193813-1 1999 BACKGROUND: The role of angiotensin II (Ang II) in the systemic and renal responses to acute nitric oxide (NO) synthesis inhibition has not been studied in detail in healthy humans. Nitric Oxide 93-105 angiotensinogen Homo sapiens 40-46 10319084-4 1999 Moreover, the production of AII is interrelated with the vasodilator substances bradykinin, nitric oxide, and prostaglandins E2 and I2 (prostacyclin). Nitric Oxide 92-104 angiotensinogen Homo sapiens 28-31 9707267-4 1998 Angiotensin II blockade also diminishes the production of superoxide anion, which inactivates ambient nitric oxide. Nitric Oxide 102-114 angiotensinogen Homo sapiens 0-14 9369252-9 1997 The nitric oxide donor was most effective in reducing thymidine incorporation when added 12 hours after angiotensin II, whereas the metabolite N-acetylpenicillamine had no effect at any time. Nitric Oxide 4-16 angiotensinogen Homo sapiens 104-118 11324535-4 1998 Nitric oxide (NO) donor SIN-1 inhibited AT II secretion significantly under normoxic condition, but NO synthase inhibitor L-nitro-arginine (LNA) eliminated the inhibitory effect of anoxia on AT II autocrine and promoted AT II release. Nitric Oxide 0-12 angiotensinogen Homo sapiens 40-45 9592707-5 1998 Control of coronary vasomotor tone and proliferation processes within the vessel wall are both determined by the redox equilibrium of nitric oxide (NO) and superoxide radicals (O2-), induced by angiotensin II. Nitric Oxide 134-146 angiotensinogen Homo sapiens 194-208 9548398-0 1998 A nitric oxide donor NOC 7 suppresses renal responses induced by norepinephrine and angiotensin II in the NO-depleted denevated rabbit kidney. Nitric Oxide 2-14 angiotensinogen Homo sapiens 84-98 9548398-1 1998 Intrarenal arterial infusion of norepinephrine (30 ng/kg per min) or of angiotensin II (4 ng/kg per min) reduced the glomerular filtration rate and urinary Na+ excretion in denervated kidneys of anesthetized rabbits pretreated intrarenally with a nitric oxide (NO) synthase inhibitor N(omega)-nitro-L-arginine methyl ester (50 microg/kg per min). Nitric Oxide 247-259 angiotensinogen Homo sapiens 72-86 9857379-10 1998 Ang II (1-7) exhibits direct and indirect effects, the latter resulting from Ang II (1-7)-dependent formation of nitric oxide and vasodilatory prostaglandins. Nitric Oxide 113-125 angiotensinogen Homo sapiens 0-6 9857379-10 1998 Ang II (1-7) exhibits direct and indirect effects, the latter resulting from Ang II (1-7)-dependent formation of nitric oxide and vasodilatory prostaglandins. Nitric Oxide 113-125 angiotensinogen Homo sapiens 77-83 9857381-2 1998 Nitric oxide (NO) and endothelin (ET-1) are involved in the regulation of renin release and modulate the vasoconstrictive and fibrogenic effects of angiotensin II. Nitric Oxide 0-12 angiotensinogen Homo sapiens 148-162 9453259-0 1997 The role of basally synthesized nitric oxide in modulating the renal vasoconstrictor action of angiotensin II. Nitric Oxide 32-44 angiotensinogen Homo sapiens 95-109 9291199-5 1997 Our premise was that if renal vasodilation induced by ACEI involves kinins, prostaglandins, and/or nitric oxide, vasoconstrictor responses to Ang II would be blunted. Nitric Oxide 99-111 angiotensinogen Homo sapiens 142-148 9359998-1 1997 Stimulated release of vasodilator prostaglandins and nitric oxide by angiotensin II may counteract the vasoconstrictor effects of this octapeptide. Nitric Oxide 53-65 angiotensinogen Homo sapiens 69-83 9422848-7 1997 Angiotensin II may also promote chronic hypertension by modulating the vascular redox state and promoting the catabolism of the endothelium-derived nitric oxide, an endogenous inhibitory vasodilator. Nitric Oxide 148-160 angiotensinogen Homo sapiens 0-14 9266887-1 1997 STUDY OBJECTIVE: To investigate the effect of short-term inhalation of nitric oxide (NO) on transpulmonary angiotensin II formation in patients with severe ARDS. Nitric Oxide 71-83 angiotensinogen Homo sapiens 107-121 9200737-0 1997 Angiotensin II interacts with nitric oxide-cyclic GMP pathway in the central control of drinking behaviour: mapping with c-fos and NADPH-diaphorase. Nitric Oxide 30-42 angiotensinogen Homo sapiens 0-14 9200737-10 1997 Extensive co-distribution of NADPH-diaphorase-stained cells and those expressing c-fos in response to intracerebroventricular injection of angiotensin II, especially in the median preoptic nucleus, imply that nitric oxide might participate in the mechanism of angiotensin II-induced drinking behaviour. Nitric Oxide 209-221 angiotensinogen Homo sapiens 139-153 9145776-3 1997 The angiotensin II- and the norepinephrine-induced renal responses were suppressed during simultaneous infusion of a spontaneous nitric oxide donor 1-hydroxy-2-oxo-3-(N-methyl-3-aminopropyl)-3-methyl 1-triazene (NOC 7, 30 ng/kg per min) which itself had little influence on the renal parameters. Nitric Oxide 129-141 angiotensinogen Homo sapiens 4-18 9200737-10 1997 Extensive co-distribution of NADPH-diaphorase-stained cells and those expressing c-fos in response to intracerebroventricular injection of angiotensin II, especially in the median preoptic nucleus, imply that nitric oxide might participate in the mechanism of angiotensin II-induced drinking behaviour. Nitric Oxide 209-221 angiotensinogen Homo sapiens 260-274 9200737-11 1997 However, a low rate of co-localization of the two markers to individual cells suggests that angiotensin II stimulated the production of nitric oxide and c-Fos in different populations of neurons. Nitric Oxide 136-148 angiotensinogen Homo sapiens 92-106 8950064-5 1996 The heptapeptide angiotensin-(1-7) appears to be critically involved in regulating the angiotensinogen activity of AII through stimulation of vasodilator prostaglandins and release of nitric oxide. Nitric Oxide 184-196 angiotensinogen Homo sapiens 115-118 9127615-4 1997 Because angiotensin II inhibits fibronectin, stimulates expression of plasminogen activator inhibitors, and degrades bradykinin, thereby impairing production of nitric oxide, ACE and the RAS are also involved in thrombosis and fibrinolysis. Nitric Oxide 161-173 angiotensinogen Homo sapiens 8-22 9127615-5 1997 The favorable effects of ACE inhibition on endothelial function and, potentially, on cardiovascular morbidity and mortality are believed to result not only from angiotensin II suppression but also its consequent bradykinin preservation and nitric oxide production. Nitric Oxide 240-252 angiotensinogen Homo sapiens 161-175 9429840-1 1997 The angiotensin II-nitric oxide balance. Nitric Oxide 19-31 angiotensinogen Homo sapiens 4-18 21232296-4 1996 Nitric oxide is considered as an example of a paracrine agent that can antagonize either the hemodynamic or cellular effects of angiotensin II during both physiological and pathological processes. Nitric Oxide 0-12 angiotensinogen Homo sapiens 128-142 8762089-3 1996 In this study, we have investigated the mechanisms controlling the release by AII of two endothelial-derived vasorelaxants, prostacyclin (PGI2) and nitric oxide (NO). Nitric Oxide 148-160 angiotensinogen Homo sapiens 78-81 24178685-0 1996 Parallel regulation of arginine transport and nitric oxide synthesis by angiotensin II in vascular smooth muscle cells role of protein kinase C. Experiments were performed to characterize arginine transport in vascular smooth muscle cells (SMCs) and the effect of angiotensin II (Ang II) on this process. Nitric Oxide 46-58 angiotensinogen Homo sapiens 72-86 8549068-16 1995 This study demonstrates that primary cultures of human proximal tubular cells can be stimulated to produce nitric oxide by both atrial natriuretic factor and angiotensin II. Nitric Oxide 107-119 angiotensinogen Homo sapiens 158-172 8667214-0 1996 Nitric oxide mediates the inhibitory action of platelet-activating factor on angiotensin II-induced renal vasoconstriction, in vivo. Nitric Oxide 0-12 angiotensinogen Homo sapiens 77-91 8834166-3 1996 Furthermore, renal responses to angiotensin II are reviewed with respect to intraluminal angiotensin II concentrations, and interactions with nitric oxide on the afferent arteriole and the tubuloglomerular feedback system. Nitric Oxide 142-154 angiotensinogen Homo sapiens 32-46 8667214-4 1996 The preferential inhibitory effect of platelet-activating factor on angiotensin II-mediated renal vasoconstriction was mimicked by the intrarenal infusion of either 0.2 to 5 micrograms/min/kg methacholine (endothelium-dependent vasodilator) or 2 micrograms/min/kg sodium nitroprusside (nitric oxide donor). Nitric Oxide 286-298 angiotensinogen Homo sapiens 68-82 8667214-5 1996 After inhibition of nitric oxide synthesis with NG-monomethyl-L-arginine, intrarenal infusion of PAF or methacholine reduced angiotensin II-mediated renal vasoconstriction significantly less than that observed in the absence of NG-monomethyl-L-arginine. Nitric Oxide 20-32 angiotensinogen Homo sapiens 125-139 8667214-6 1996 Therefore, this study provides evidence that the shared ability of platelet-activating factor and methacholine to selectively reduce angiotensin II-mediated renal vasoconstriction involves endothelium-derived nitric oxide. Nitric Oxide 209-221 angiotensinogen Homo sapiens 133-147 7624014-2 1995 Application of the nitric oxide (NO) donor sodium nitroprusside inhibited the activity in 10 out of 12 duck SFO neurons, 8 of which were in addition excited by ANGII. Nitric Oxide 19-31 angiotensinogen Homo sapiens 160-165 8544396-0 1995 Nitric oxide antagonizes the actions of angiotensin II to enhance tubuloglomerular feedback responsiveness. Nitric Oxide 0-12 angiotensinogen Homo sapiens 40-54 8544396-1 1995 The present study was designed to investigate whether nitric oxide (NO) antagonizes angiotensin II (Ang II) in modulating the tubuloglomerular feedback (TGF) system. Nitric Oxide 54-66 angiotensinogen Homo sapiens 84-98 8544396-1 1995 The present study was designed to investigate whether nitric oxide (NO) antagonizes angiotensin II (Ang II) in modulating the tubuloglomerular feedback (TGF) system. Nitric Oxide 54-66 angiotensinogen Homo sapiens 100-106 8525141-8 1995 These results suggest that (1) AII modulates the amino acid-induced hyperemia through its inhibitory effect on proximal tubular reabsorption and activation of the tubuloglomerular feedback system, and (2) that the expression of the modulatory effect of AII may depend on the interaction between AII and other intrarenal systems like nitric oxide. Nitric Oxide 333-345 angiotensinogen Homo sapiens 31-34 8549068-0 1995 Atrial natriuretic factor and angiotensin II stimulate nitric oxide release from human proximal tubular cells. Nitric Oxide 55-67 angiotensinogen Homo sapiens 30-44 8549068-5 1995 The ability of angiotensin II, atrial natriuretic factor and c(4-23) atrial natriuretic factor to stimulate nitric oxide production was investigated in primary cultures of human proximal tubular cells. Nitric Oxide 108-120 angiotensinogen Homo sapiens 15-29 8549068-11 1995 Incubation of human proximal tubular cells with angiotensin II, atrial natriuretic factor or c(4-23) atrial natriuretic factor produced a dose- and time-dependent increase in nitric oxide production, which was inhibited in the presence of NG-monomethyl-L-arginine. Nitric Oxide 175-187 angiotensinogen Homo sapiens 48-62 8019744-1 1994 The angiotensin I (AI) metabolite, A(1-7), elicited a concentration-dependent dilator response (ED50 > or = 2 microM) in porcine coronary artery rings which was markedly attenuated by the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine, and abolished after removal of the endothelium. Nitric Oxide 191-203 angiotensinogen Homo sapiens 4-17 1982771-4 1990 Subpopulations of endothelial cells store and release a variety of substances, including acetylcholine, substance P, ATP, 5-hydroxytryptamine, vasopressin and angiotensin II, that act on receptors on endothelial cells and lead to the production of endothelium-derived relaxing factor (identified as nitric oxide) which, in turn, produces vasodilation in response to changes in flow and hypoxia. Nitric Oxide 299-311 angiotensinogen Homo sapiens 159-173 34580391-10 2021 Glucose provocation is known to cause insulin-induced vasodilation through the nitric oxide pathway, and this study indicates that this is facilitated through the interactions of the RAS (angiotensinogen) and kallikrein-kinin (kininogen-1) systems. Nitric Oxide 79-91 angiotensinogen Homo sapiens 188-203 34266605-5 2021 Under physiologic conditions, tonic sympathetic inhibition driven by a nitric oxide-gamma-aminobutyric acid-mediated mechanism is dominant, but in pathologic situation such as heart failure there is a switch from inhibition to sympathoexcitation driven by glutamate and angiotensin II. Nitric Oxide 71-83 angiotensinogen Homo sapiens 270-284 34266605-6 2021 Angiotensin II, reactive oxygen species, and hypoxia as a result of myocardial infarction/ischemia alter the tightly regulated posttranslational protein-protein interaction of CAPON (carboxy-terminal postsynaptic density protein ligand of neuronal nitric oxide synthase (NOS1)) and PIN (protein inhibitor of NOS1) signaling mechanism. Nitric Oxide 248-260 angiotensinogen Homo sapiens 0-14 8169847-0 1994 Vasodilator-derived nitric oxide inhibits fetal calf serum- and angiotensin-II-induced growth of renal arteriolar smooth muscle cells. Nitric Oxide 20-32 angiotensinogen Homo sapiens 64-78 34074111-3 2021 Even though both drug groups block angiotensin II, ACE inhibitors typically reduce the degradation of bradykinin, which leads to the release of nitric oxide and prostaglandins with subsequent vasodilation. Nitric Oxide 144-156 angiotensinogen Homo sapiens 35-49